Advertisement

Topics

Cellectis SA Company Profile

17:18 EST 24th November 2017 | BioPortfolio

Cellectis is the worldwide leader in the research, development and commercialization of rational genome engineering technologies. Cellectis proprietary technologies and platform are based upon a naturally occurring class of DNA endonucleases, the Meganucleases and DNA recombination.The DNA recognition and function of Meganucleases can be used to target a unique DNA break at a specific location within living cells. Meganucleases are acting in a site-directed fashion by inducing a highly efficient targeted DNA recombination. Rational genome engineering based on DNA recombination and Meganucleases represents an enabling technology that can be applicable to biotechnological R&D and industrial applications. More.

Location

102 route de Noisy
Romainville
Cedex
93235
France

Contact

Phone: 33 1 41 83 99 00
Fax: 33 1 41 83 99 03
Email: mail@cellectis.com


News Articles [92 Associated News Articles listed on BioPortfolio]

Cellectis Granted T Cell CRISPR Patent in Europe

The bitter patent feud over CRISPR , a gene-editing tool with unprecedented potential, continues in the United States. Meanwhile, French biotech Cellectis is staking a claim to the technology in Europ...

FDA Lifts Hold on Cellectis’s “Off the Shelf” CAR-T, With Caveats

The FDA has cleared Cellectis to resume testing an experimental “off the shelf” type of cell therapy, so long as it follows a new set of measures meant to quell the safety concerns that caused the...

Cellectis given another shot at off-the-shelf CAR-T

It is easy to forget the very real dangers that CAR-T treatment present to patients after Novartis and Gilead both successfully scored approvals on the back of impressive data, and with Juno Therapeut...

The dawn of a new beginning for Cellectis?

Paris – amazingly it’s now 3 years since we interviewed Cellectis (NASDAQ: $CLLS) CEO André Choulika and CSO Philippe Duchateau…

Cellectis advances CAR-T therapy study with dosing of its first participant

The early-stage clinical trial that will evaluate the efficacy and safety of UCART123, Cellectis' chimeric antigen receptor T -More- 

Death Of First CAR-T Patient Forces Trial Halt For Cellectis

ENDPOINTS NEWS |  The FDA has forced Cellectis to slam the brakes on two clinical trials of its off-the-shelf-version of a CAR-T therapy after their first patient was killed by a lethally toxic react...

Cellectis doses first patient with BPDCN in phase I study of UCART123

Cellectis, a clinical─stage biopharmaceutical company focused on developing immunotherapies based on gene─edited CAR T─cells (UCART), announced that the first patient with Blastic Plasmacytoid

FDA holds trials of Cellectis’ cell therapy after patient death

US regulators have placed on hold studies of French drugmaker Cellectis’ CAR-T therapy following a patient fatality.

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [9 Associated Companies listed on BioPortfolio]

Cellectis

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools, meganucleases. These molecular scissors enable targeted modifications ...

Cellectis Group

Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis A...

Cellectis bioresearch

Cellectis bioresearch was incorporated as a subsidiary of Cellectis SA (Alternext: ALCLS) in June 2008. It provides life science researchers with ready-to-use research tools for genome customization. ...

Cellectis S.A.

Cellectis S.A. is a world leader in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery a...

Cellectis therapeutics

Cellectis is a pioneer in the field of genome engineering. The company designs and markets innovative tools -meganucleases. These molecular scissors enable targeted modifications to DNA, with applicat...

More Information about "Cellectis SA" on BioPortfolio

We have published hundreds of Cellectis SA news stories on BioPortfolio along with dozens of Cellectis SA Clinical Trials and PubMed Articles about Cellectis SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Cellectis SA Companies in our database. You can also find out about relevant Cellectis SA Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

DNA sequencing
DNA sequencing is the process of determining the precise order of nucleotides within a DNA molecule. During DNA sequencing, the bases of a small fragment of DNA are sequentially identified from signals emitted as each fragment is re-synthesized from a ...

Biotechnology
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...


Corporate Database Quicklinks



Searches Linking to this Company Record